-
Piper Jaffray Overweight On Medtronic
Thursday, August 18, 2011 - 7:29am | 120Piper Jaffray is out with a research report on Medtronic, Inc. (NYSE: MDT) and it has an Overweight rating and $44 price target on shares. In a note to clients, Piper Jaffray writes, "We see favorable near-term risk reward for the FQ1 report. MDT shares have traded off more severely than a...
-
Mad Money Lightning Round: Cramer Likes Crocs, Alcoa
Thursday, August 18, 2011 - 4:16am | 332On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Crocs (NASDAQ: CROX) is a “great story. If it goes back down, I'm going to recommend it." For Covidien (NYSE: COV), he said, "You hold on and buy more. That is a great company that is a buy, buy, buy." Cramer said that Alcoa (...
-
Notable Put Options Activity in Covidien
Wednesday, August 17, 2011 - 1:24pm | 88Shares of Covidien (NYSE: COV) are higher on the session by 0.44%, currently trading at $50.12. The stock has been moving largely higher over the past week and is currently trading above the 200-day moving average. Options traders are focusing on puts today. A short while ago the August2011 $52....
-
Notable Call Options Activity in ResMed
Wednesday, August 17, 2011 - 11:52am | 112Shares of ResMed (NYSE: RMD) are lower on the session by 0.34%, currently trading at $29.01. The stock has been moving largely lower over the past two months and is currently trading below the 50-day average. Options traders are focusing on calls today. A short while ago the September 2011 $30.00...
-
Piper Jaffray Reiterates Overweight on MAKO Surgical
Wednesday, August 17, 2011 - 9:18am | 81Piper Jaffray is out with its report today on MAKO Surgical (NASDAQ: MAKO), reiterating Overweight. In its report, Piper Jaffray writes, "We continue to view MAKO's surgical robotic arm as one of the most compelling innovations in orthopaedics in recent years. We reiterate our Overweight rating on...
-
MELA Sciences Issues Statement on FDA's New Draft Guidance on Pivotal Clinical Trials
Wednesday, August 17, 2011 - 8:54am | 330MELA Sciences, Inc. (NASDAQ: MELA) issued the following statement regarding the U.S. Food and Drug Administration's (FDA) draft guidance on Design Considerations for Pivotal Clinical Investigations for Medical Devices, including those conducted to support Premarket Approval applications. The draft...
-
Citi Upgrading Hospira
Wednesday, August 17, 2011 - 8:08am | 93Citi Investment Research is upgrading shares of Hospira (NYSE: HSP) to Hold, and is raising its price target to $49 from $43. In a note to clients, Citi Investment Research writes, "HSP's discounted valuation (11x F12M P/E) and stock underperformance YTD adequately reflect the transition from a...
-
Benzinga's Top Upgrades
Wednesday, August 17, 2011 - 7:42am | 128Sterne Agee upgraded Dick's Sporting Goods Inc (NYSE: DKS) from “sell” to “neutral.” DKS' shares closed at $32.78 yesterday. Dick's Sporting Goods' PEG ratio is 1.02. Analysts at JP Morgan upgraded Motorola Mobility Holdings Inc (NYSE: MMI) from “underweight” to “neutral.” MMI's shares closed at $...
-
Citigroup Upgrades Hospira To Hold, PT To $49
Wednesday, August 17, 2011 - 6:17am | 26Citigroup has upgraded Hospira (NYSE: HSP) from Sell to Hold and has raised the price target from $43 to $49.
-
UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from $15.85 to $15.35
Tuesday, August 16, 2011 - 9:44am | 100Feltl and Company has published a research report on DexCom Inc. (NASDAQ: DXCM) upgrading the company. In the report, Feltl & Company wrote, "The recent market correction has seen DexCom sell off to near its 52-week low. This has lowered the company's enterprise value to ~$650 million or...
-
Market Update
Tuesday, August 16, 2011 - 9:37am | 209Shares of AngioDynamics Inc (NASDAQ: ANGO) fell about 0.6% after the company named Joseph M. DeVivo President and Chief Executive Officer, effective September 7, 2011. Shares of Tata Motors Ltd (NYSE: TTM) fell about 3.6% after the company reported a 6% y/y drop in its global vehicle sales for...
-
Quidel Receives CE Mark for Its Sofia Fluorescent Immunoassay Analyzer and Influenza A+B FIA Test
Tuesday, August 16, 2011 - 9:01am | 201Quidel Corporation (NASDAQ: QDEL) announced today that it has received the CE Mark for its Sofia® Fluorescent Immunoassay Analyzer and for its Sofia® Influenza A+B Fluorescent Immunoassay. Sofia is the brand name for Quidel's next generation, immunoassay system. The Sofia Analyzer and Sofia...
-
Feltl Upgrades DexCom To Buy, PT Raised To $15.85
Tuesday, August 16, 2011 - 8:53am | 27Feltl & Company has upgraded DexCom (NASDAQ: DXCM) from Hold to Buy and has lowered the price target from $15.85 to $15.35.
-
Syneron Beauty Receives FDA Clearance for New Tanda Luxe Device for Treatment of Periorbital Wrinkles at Home
Tuesday, August 16, 2011 - 8:00am | 227Syneron Beauty, a subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS), announced today that it has received 510(k) clearance from the United States Food and Drug Administration to market the new Tända™ Luxe Light Emitting Diode device to consumers. The new device is a next-generation evolution of the...
-
Piper Jaffray Reiterates Overweight on Gen-Probe
Tuesday, August 16, 2011 - 7:46am | 134Piper Jaffray is out with its report today on Gen-Probe (NASDAQ: GPRO), reiterating Overweight. In its report, Piper Jaffray writes, "Our internet diligence reveals increasing search activity on the terms/phrases Trichomonas, STD Trichomonas, what is Trichomonas, and Trichomonas vaginalis, which...